Skip to main content
Premium Trial:

Request an Annual Quote

Halo Precision Diagnostics: John Craighead

Halo Precision Diagnostics has appointed John Craighead its chief operating officer and CFO. He has more than two decades of experience in the life sciences and financial services sectors and recently was CFO and head of corporate development at biopharmaceutical firm Elpiscience. Before that, Craighead was VP of strategy, corporate development, and investor relations at Grail, and he has held leadership posts at Sanofi, Atara Biotherapeutics, Lehman Brothers, and Human Genome Sciences. Menlo Park, California-based Halo Precision Diagnostics leverages advanced imaging and molecular diagnostic technologies for early disease detection. Disease areas of interest include prostate cancer, breast cancer, and cardiovascular and neurodegenerative diseases.

The Scan

Positive Framing of Genetic Studies Can Spark Mistrust Among Underrepresented Groups

Researchers in Human Genetics and Genomics Advances report that how researchers describe genomic studies may alienate potential participants.

Small Study of Gene Editing to Treat Sickle Cell Disease

In a Novartis-sponsored study in the New England Journal of Medicine, researchers found that a CRISPR-Cas9-based treatment targeting promoters of genes encoding fetal hemoglobin could reduce disease symptoms.

Gut Microbiome Changes Appear in Infants Before They Develop Eczema, Study Finds

Researchers report in mSystems that infants experienced an enrichment in Clostridium sensu stricto 1 and Finegoldia and a depletion of Bacteroides before developing eczema.

Acute Myeloid Leukemia Treatment Specificity Enhanced With Stem Cell Editing

A study in Nature suggests epitope editing in donor stem cells prior to bone marrow transplants can stave off toxicity when targeting acute myeloid leukemia with immunotherapy.